Table I.

Expression of various markers on CD4+CD25+ and CD4+CD25 cells from the SDLN of BALB/c mice treated four days earlier with vehicle or 1,25(OH)2D3

Marker (GMFI)aSkin treatmentCD4+CD25+CD4+CD25
CD44Vehicle23.0 ± 2.66.7 ± 1.0
1,25(OH)2D322.3 ± 3.25.7 ± 0.9
CD45RBVehicle29.3 ± 2.0144.7 ± 2.7
1,25(OH)2D324.3 ± 4.9154.7 ± 11.2
CD54Vehicle31.7 ± 2.07.3 ± 0.3
1,25(OH)2D336.0 ± 4.09.0 ± 1.0
Marker (%)aSkin treatmentCD4+CD25+CD4+CD25
CD62LhiVehicle57.8 ± 1.277.5 ± 1.7
1,25(OH)2D359.3 ± 2.679.7 ± 1.1
CD69+Vehicle34.7 ± 0.418.7 ± 0.4
1,25(OH)2D335.8 ± 0.618.9 ± 1.0
CD103+Vehicle26.1 ± 1.911.1 ± 0.6
1,25(OH)2D324.5 ± 0.510.6 ± 1.1
  • a Data are shown as mean ± SEM for three experiments where the CD3+CD4+ T cells from the SDLN of three mice per treatment were tested for the expression of these markers by flow cytometry. GMFI, Geometric mean fluorescence index; %, percentage of cells that expressed high levels (hi) or were positive (+) for the particular marker.